MedTrace Logo

Safety and Effectiveness Study of BCI-540 Versus Placebo in the Treatment of Major Depressive Disorder With Concomitant Anxiety

NCT00621270 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 115

Last updated 2011-10-24

No results posted yet for this study

Summary

The purpose of this study is to determine whether BCI-540 80 mg given once daily (q.d.) or three times daily (t.i.d.) is effective in the treatment of major depression with concomitant anxiety.

Conditions

Interventions

DRUG

BCI-540

BCI-540 80 mg once (q.d.) or three times (t.i.d.) a day versus placebo

Sponsors & Collaborators

  • BrainCells Inc.

    lead INDUSTRY

Principal Investigators

  • Allan H. Young, MB ChB, MPhil, PhD, FRCPsych · Institute of Mental Health, Dept. of Psychiatry, University of British Columbia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2009-10-31
Completion
2009-10-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00621270 on ClinicalTrials.gov